Dr
Daniel
Woollaston

Partner & Patent Attorney

Leeds Office York Office

Chemistry

Telephone. +44(0) 113 233 0100
Mobile. +44(0) 738 487 7685
Email. [email protected]

Experience

Since joining HGF in 2010, much of Daniel’s work has concerned the drafting and prosecuting of patent applications across a broad spectrum of chemical sciences, but particularly in the fields of pharmaceuticals, medicinal chemistry, organic chemistry, graphene and other 2D materials, chemical engineering, carbon capture, dyes, agrochemicals, and resins for use in 3D printers. Daniel also has experience in advising on freedom to operate issues.

Daniel has formulated complex IP strategies for several award winning UK pharmaceutical companies.

He has worked extensively with a number of UK Russell Group universities for whom he has provided patentability opinions and drafted and prosecuted to grant worldwide patent applications in a range of technically complex chemistry related subject matters.

Qualifications

Patent Attorney

Chartered (UK)
European


MCHEM

University of Oxford

PHD

Organic Chemistry; University of Oxford

Conferences: 2021

January 14th 2021

HGF IP in Healthcare Virtual Conference 2021

Speaker

Event details

Related News

Artificial intelligence inventions in healthcare – can you patent them in Europe?

Artificial Intelligence (AI) has moved from the realm of science fiction firmly into the mainstream of technological innovation. Trained AI models in some cases are able to perform data analysis …

Read article

Patenting digital mental health

Mental health and behavioural disorders have a profound impact on wellbeing worldwide, with an estimated 13% of the global population suffering from a mental health or substance use disorder [1]. …

Read article

Patenting antibodies in the US and Europe

Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …

Read article

Patentability of Simulations in Europe

Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …

Read article

Blockbuster blood thinning patent revoked

Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …

Read article
Event - 10th May 2022

The HGF IP in Healthcare Conference 2022

After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …

Event details
Event - 10th May 2022

HGF UPC events in Germany and Austria 2022

HGF is holding a webinar and an in-person event covering the UPC in Germany and Austria this Spring. The provisional phase of the Unified Patent Court (UPC) is now underway …

Event details
Event - 23rd March 2022

HGF webinar: Getting your first filing right

HGF hosted a webinar on Wednesday 23rd March on Getting your first filing right. One of the most often asked questions of patent attorneys is: “when should we file?” Both …

Event details

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.